CARsgen Therapeutics Holdings Limited (2171.HK)
Develops CAR-T cell therapies to treat blood cancers and solid tumors in China
13.50+0.02%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-31.1%
The outlook
CARsgen trades at 13.5 with minimal momentum today, sitting well below both its 50- and 200-day averages and near the lower end of its 52-week range. Analyst coverage leans bullish on valuation, with the average price target about 58% above the current level, though overall sentiment scores bearish at 24/100.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range15% of the way from its 52-week low to high
Price targetAvg target +58% vs current price
Analyst price target
~12-month · 2 analysts21.26average target+57.5% vs now
Now 13.50
Low 16.18High 26.35
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$7.69B
52-wk high
28.60
52-wk low
10.87
50-day avg
15.84
200-day avg
16.73
Trailing P/E
—